Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials
Author:
Funder
Cancer Council SA
Pfizer
National Breast Cancer Foundation
Cancer Council SA’s
Publisher
Elsevier BV
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference19 articles.
1. Cancer immunotherapy using checkpoint blockade;Ribas;Science,2018
2. Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance;Park;Exp Mol Med,2018
3. Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers;Hopkins;Br J Cancer,2017
4. Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer;Prelaj;Eur J Cancer,2019
5. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH);Peters;J Clin Oncol,2017
Cited by 72 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Early Changes in LIPI Score Predict Immune-Related Adverse Events: A Propensity Score Matched Analysis in Advanced Non-Small Cell Lung Cancer Patients on Immune Checkpoint Blockade;Cancers;2024-01-20
2. Efficacy and safety of camrelizumab in patients with first-line and second- line therapy for esophageal squamous cell carcinoma: A multicenter, prospective, real-world study;2023-11-08
3. The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective;Frontiers in Immunology;2023-09-11
4. Prognostic value of the Lung Immune Prognostic Index for HER-2-negative metastatic gastric cancer;Biomarkers in Medicine;2023-09
5. Correlation of Lung Immune Prognostic Index With Efficacy of PD-1/PD-L1 Inhibitor Combined With Chemotherapy and Prognosis in Patients With Advanced Non–Small Cell Lung Cancer;American Journal of Clinical Oncology;2023-08-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3